Avacta Group Plc (AIM: AVCT)

Market Cap	173.80M
Revenue (ttm)	22.62M
Net Income (ttm)	-25.89M
Shares Out	365.90M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	700,754
Open	47.96
Previous Close	48.00
Day's Range	45.53 - 49.00
52-Week Range	39.50 - 119.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 4, 2025

About Avacta Group

Avacta Group Plc develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. The company operates through Diagnostics and Therapeutics segments. It provides its proprietary Affimer and pre|CISION technology platforms, which is used to deliver a portfolio of differentiated th therapeutic and diagnostic products that addresses various markets. The company develops AVA6000, a peptide drug conjugate form of doxorubicin that is in Phase I clinical trial to treat local...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 154
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: AVCT

Financial Performance

In 2023, Avacta Group's revenue was 23.25 million, an increase of 140.83% compared to the previous year's 9.65 million. Losses were -24.95 million, -31.90% less than in 2022.